Companies in #Targeted Drug Delivery (TAMP therapy)
Found 1 company operating in this sector.
RenovoRx is a clinical-stage life-sciences company developing targeted oncology combination therapies, anchored by RenovoCath, a novel FDA-cleared local drug-delivery catheter for cancer treatment, and the TIGERPAC pivotal trial evaluating RenovoCath-delivered gemcitabine in locally advanced pancreatic cancer. The company reported record revenue (+115% year-over-year) and full enrollment in the pivotal TIGERPAC trial in its Q2 2026 results, regained Nasdaq minimum-bid-price compliance in August 2026, and holds a new U.S. patent allowance covering the RenovoCath dual-occlusion technology.